MEDIAN PARTNERS WITH TOP 10 ONCOLOGY PHARMA.

Median Technologies has signed an initial agreement with a Top 10 oncology pharmaceutical company to conduct AI-based imaging biomarker discovery on the clinical data of a drug candidate. The agreement could lead to a broader collaboration between the two companies. Median's Imaging Lab, a dedicated entity of its iCRO Business Unit, will provide the pharmaceutical company with advanced AI-based decision-making capabilities using patients' imaging data. The goal is to identify specific digital signatures (imaging biomarkers) from images that can provide meaningful information on the drug responder/non-responder status of patients. These imaging biomarkers could potentially be used as companion diagnostics to select patients who are most likely to benefit from the drug. [Extracted from the article]

Copyright of Imaging Update is the property of Worldwide Videotex and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)